Nyrada (ASX:NYR) said no issues were raised by the safety review committee after assessing phase one clinical trial data of its drug candidate NYR-BI03, developed to reduce brain and heart damage from brain injury and stroke, according to a Wednesday filing with the Australian bourse.
The committee assessed cumulative safety and pharmacokinetic data from the first three cohorts of the trial, the filing said.
Recruitment for the fourth cohort has been completed, the company added.
Final results from the phase one trial are expected in the third quarter of the year.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.